Logo Image
|Articles|June 1, 2006

Key players in Medicare Part D

Privatization of Medicare Part D has led to the emergence of manyplayers, both large and small. Navigating CMS regulations andsubsequent guidance has resulted in some administrative burdens, aswell as the inability to employ many managed care techniques, sayexperts.

As a result, "you are going to see consolidation of Medicare Part D providers and only those providers that can successfully administer these plans will have substantial competitive advantage and will remain long-term players," says Alexander M. Gilderman, PharmD, vice president, clinical programs at Ventegra, a La Jolla, Calif.-based contracting service organization.

Related Content

Latest CME

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment
Video

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

View more
27th Annual International Lung Cancer Congress®
Video

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

View more
Tennessee Oncology Practice Society
Virtual Event

Tennessee Oncology Practice Society

2 Sessions are Available!

View more
20th Annual New York Lung Cancers Symposium®
Video

20th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Jamie Chaft, MD

View more
Hot Seat: Converging Lines in the Management of RAS-Altered Cancers
Video

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

View more
From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS
Video

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

View more
Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care
Video

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Jacob Sands, MD; Marina Chiara Garassino, MD; Eric K. Singhi, MD

View more
Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes
Video

Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes

Charles M. Rudin, MD, PhD; Alex A. Adjei, MD, PhD; Millie Das, MD

View more